ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Failure patterns and the influence of the TNM staging systems on prognosis in limited disease small cell lung Cancer (SCLC): the Turkish Oncology Group (TOG) study.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Machine Learning-Based Prediction of Brain Metastasis at Initial Diagnosis in Small-Cell Lung Cancer: Model Development and SHAP Interpretation Study.Cancer reports (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine recurrence patterns and prognostic factors in limited disease SCLC (LD-SCLC) and evaluate the effect of TNM classification on prognosis. MATERIAL AND
methodsWe retrospectively evaluated 266 patients with LD-SCLC who underwent curative chemoradiotherapy ± prophylactic cranial irradiation (PCI) between 2003 and 2016. These patients were recruited from 10 centers and restaged using the 7th and 8th TNM staging systems. We assessed the impact of TNM stage, age, gender, and PCI on all survival outcomes through univariate and multivariate analyses. Survival rates were calculated using the Kaplan-Meier method.
resultsThe median follow-up period was 42 months. In all cases, the 2- and 5-year local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and overall survival (OS) rates were 63.4-41.8%, 50.6-43.2%, and 50.9-27.7%, respectively. In the Cox regression analysis, N2-N3 disease and not receiving PCI were identified as poor prognostic factors for DMFS. In contrast, N2 disease, T4 stage according to the 8th TNM system, not receiving PCI, and thoracic RT doses < 60 Gy were recognized as prognostic factors negatively associated with OS. It was also observed that having N3 disease increases the risk of developing brain metastasis (BM) by a factor of 2.6.
conclusionIn our cohorts, the N category emerged as the most significant prognostic factor for overall survival, distant metastasis-free survival, and the development of brain metastasis. Considering that the definition of limited disease encompasses a broad spectrum of patients, TNM staging may be more beneficial in predicting patient prognosis and guiding treatment decisions, as suggested.
Indexed as
Identifiers
41134441What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.